VAXX Stock Crashes 99.5% on NASDAQ: Vaxxinity Inc. Hits Record Low

VAXX stock has collapsed dramatically, losing 99.5% of its value to trade at just $0.0001 per share on NASDAQ as of April 28, 2026. Vaxxinity, Inc., the Dallas-based biotechnology company, has seen its market capitalization shrink to just $2.2 million, a stunning reversal from its IPO in November 2021. The biotech firm, which develops neurology and coronavirus vaccine candidates, now faces existential questions about its pipeline and financial runway. With negative earnings, mounting cash burn, and a stock price near penny stock territory, VAXX stock represents one of the market’s most severe biotechnology failures this year.

VAXX Stock Price Collapse: What Happened

VAXX stock opened at $0.0175 on April 28 but closed at $0.0001, marking a devastating single-day loss of 99.4%. The year-to-date decline stands at 5,733%, while the three-year performance shows a staggering -99.18% drop. Volume surged to 18,352 shares, well above the average of 13,105, signaling panic selling among remaining shareholders.

The stock’s 52-week range tells the story: a high of $0.05 versus a low of $0.0001. This extreme volatility reflects investor uncertainty about Vaxxinity’s clinical programs and cash position. The company’s enterprise value sits at $12.5 million against a market cap of just $2.2 million, indicating significant debt burden relative to equity value.

Financial Metrics Show Deep Distress

Vaxxinity’s financial health deteriorated sharply across all key metrics. The company reported negative earnings per share of -$0.05 with a price-to-earnings ratio of -0.35, reflecting ongoing losses. Operating cash flow per share stands at -$0.45, while free cash flow per share is -$0.46, indicating the company burns cash rapidly.

The debt-to-equity ratio reached 1.13, meaning liabilities exceed shareholder equity by a significant margin. Current ratio of 1.89 suggests short-term liquidity exists, but with negative cash burn, runway appears limited. Book value per share is just $0.11, while the stock trades at only $0.0001, representing a 99.85% discount to tangible assets. This massive valuation gap suggests the market prices in near-total loss of equity value.

Clinical Pipeline and Product Development Status

Vaxxinity’s pipeline includes several neurology-focused candidates at various clinical stages. UB-311, targeting Alzheimer’s disease through amyloid-beta aggregation, remains in phase 2 clinical trials. UB-312 for Parkinson’s disease and synucleinopathies is in phase 1, while an anti-tau candidate targets multiple neurodegenerative conditions.

The company also develops UB-313 for migraines, anti-PCSK9 for cholesterol management, and UB-612 for COVID-19 neutralization in phase 3 trials. Despite having multiple programs, none have generated revenue. With only 57 full-time employees and negative cash flow, the company struggles to advance programs efficiently. Earnings are scheduled for announcement on May 12, 2026, which may provide clarity on remaining cash and timeline.

Market Sentiment and Technical Indicators

Technical analysis reveals extreme overbought conditions despite the stock’s collapse. The Money Flow Index (MFI) reads 98.44, indicating severe overbought status. The Commodity Channel Index (CCI) at 146.87 also signals overbought territory, suggesting potential for further volatility.

The Relative Strength Index (RSI) of 57.67 sits near neutral, while the Average Directional Index (ADX) at 40.68 indicates a strong downtrend in place. Rate of Change (ROC) shows 17,400%, reflecting the extreme price movement from recent lows. On-Balance Volume (OBV) is deeply negative at -102,493, showing sustained selling pressure. Track VAXX on Meyka for real-time updates on this volatile biotech stock.

Final Thoughts

VAXX stock’s collapse to $0.0001 represents a catastrophic failure for Vaxxinity, Inc. shareholders. The company faces severe financial distress with negative cash flow, mounting debt, and a depleted market capitalization of just $2.2 million. While the clinical pipeline includes promising neurology programs, the lack of revenue and rapid cash burn create urgent questions about survival. With earnings due May 12, 2026, investors need clarity on remaining runway and strategic options. This penny stock situation demands extreme caution; the risk of total loss remains substantial despite the already-depressed valuation.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.